Tapping Microbiome Science for New Treatments and Answers to Drug Efficacy

Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to unlock new potential for stratified treatments.